Drug Identity
Active Ingredient
Ketorolac
Drug Class
Pain Management
Chemical Class
Pyrrolizine carboxylic acid
Pharmacological Group
on the basis of mechanism of action and also cl...
What is Strolac?
pain, swelling and stiffness ass...
used to treat pain, swelling and stiffness associated with arthritis
How It Works
Chemical Class
Pyrrolizine carboxylic acid
Pharmacological Group
on the basis of mechanism of action and also classified in Analgesics and Anti-inflammatory Agents pharmacological group
Ketorolac (Tromethamine) also known as Ketorolac Trometamol. It is of Synthetic origin and belongs to Pyrrolizine carboxylic acid. It belongs to Cyclo-oxygenase inhibitor pharmacological group on the basis of mechanism of action and also classified in Analgesics and Anti-inflammatory Agents pharmacological group. The Molecular Weight of Ketorolac (Tromethamine) is 255.26. Its pKa is 3.54.
How to Take It
1
Adult · IM
15 to 30 mg — 6 hourly
For 5-Days
2
Adult · Ophthalmic
0.5 % — As recommended.
As Required.To be given as drops.
3
Adult · PO
10 to 40 mg — 6 hourly
4
Adult
Scraped Dose
Symptoms and Signs Symptoms following acute NSAIDs overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care
5
Child · 2 to 16 years, To maximum of 30 mg.
1 mg/kg — As recommended.
Safety Alerts
Ketorolac (Tromethamine) is contraindicated in conditions like Asthma, Hypertension, Hypovolaemia, Peptic ulcer, Rhinitis, Renal artery stenosis, Hypersensitivity, Dehydration, Hepatic cirrhosis with ascites, Coagulation disorder, Cerebrovascular hemorrhage
Important Warnings
(see also Boxed WARNING ) The total combined duration of use of oral ketorolac tromethamine and intravenous or intramuscular dosing of ketorolac tromethamine is not to exceed 5 days in adults
Ketorolac tromethamine is not indicated for use in pediatric patients
The most serious risks associated with ketorolac tromethamine are: Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic
Minor upper gastrointestinal problems, such as dyspepsia, are common and may also occur at any time during NSAID therapy
The incidence and severity of gastrointestinal complications increases with increasing dose of, and duration of treatment with ketorolac tromethamine
Do not use ketorolac tromethamine for more than five days
However, even short-term therapy is not without risk
In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status
Side Effects
Adverse reaction rates increase with higher doses of ketorolac tromethamine. Practitioners should be alert for the severe complications of treatment with ketorolac tromethaminesuch as G.I. ulcerationbleeding and perforationpostoperative bleedingacute renal failureanaphylactic and anaphylactoid reactions and liver failure (see Boxed WARNINGWARNINGSPRECAUTIONSand DOSAGE AND ADMINISTRATION ). These NSAID-related complications can be serious in certain patients for whom ketorolac tromethamine is indicatedespecially when the drug is used inappropriately. In patients taking ketorolac tromethamine or other NSAIDs in clinical trialsthe most frequently reported adverse experiences in approximately 1% to 10% of patients are: Additional adverse experiences reported occasionally (<1% in patients taking ketorolac tromethamine or other NSAIDs in clinical trials) include: Body as a Whole: feverinfectionssepsis Cardiovascular: congestive heart failurepalpitationpallor
Drug Interactions
Ketorolac is highly bound to human plasma protein (mean 99.2%). There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs. Warfarin
Digoxin
Salicylate
and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to 10 mcg/mL. Ketorolac does not alter digoxin protein binding. In vitro studies indicate that
at therapeutic concentrations of salicylate (300 mcg/mL)
the binding of ketorolac was reduced from approximately 99.2% to 97.5%
representing a potential two-fold increase in unbound ketorolac plasma levels. Therapeutic concentrations of digoxin
warfarin
Storage
Tab, Inj Store Between 15°C-30°C. Protect from Sunlight and Moisture.
Price Intelligence
Rs 579
Servaid observed price · as of 30 July 2026
No approved ceiling matched to this exact pack and strength.
Prices across sources
ServaidRs 579
Should you consider an alternative?
Other options containing Ketorolac, and what they are not.
These contain this ingredient plus others. They are different medicines — do not swap.
TORADOL
30 MG 1 ML
+ Ketorolac Trometamol Inj, Ketorolac Tromethamine
Rs 718.2Rs 71.82/unit
No DRAP alertsMartin Dow
Toradol
30mg
+ Ketorolac Trometamol Inj, Ketorolac Tromethamine
Rs 718.2
No DRAP alertsMARTIN DOW
Ordered by lowest price per unit where a pack size is known, then by price. Order is never affected by sponsorship. Not medical advice — confirm any change with your pharmacist or doctor.
For pharma professionalsCompany, market and opportunity intelligence
Company
119
brands
121
molecules
0
alerts